Defibrotide Sodium
drug drugOn this page
Also known as DefitelioJZP-381
Summary
Defibrotide Sodium (CHEMBL3707226) is an approved oligonucleotide; indicated across 1 condition including hepatic veno-occlusive disease.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Oligonucleotide
- Indications: 1 condition
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL3707226 |
| Name | Defibrotide Sodium |
| Type | Oligonucleotide |
| Max phase | 4 |
Also known as: Defibrotide sodium, Defitelio, JZP-381, DEFIBROTIDE SODIUM
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).
| Indication | Phase | MONDO | EFO |
|---|---|---|---|
| hepatic veno-occlusive disease | 4 | MONDO:0019514 | MONDO:0019514 |
Clinical trials
Total trials: 0.
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Indicated for: hepatic veno-occlusive disease